[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367693-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367693-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-delivery-of-the-pkmyt1-inhibitor-rp-6306-mediates-panoptosis-in-pancreatic-cancer-via-mitotic-catastrophe","Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe","","Pancreatic ductal adenocarcinoma (PDAC) progresses to advanced stages, limiting surgical options and making systemic chemotherapy essential, yet existing gemcitabine-based regimens show limited efficacy with notable systemic toxicity. This study evaluates PKMYT1 as a therapeutic target and demonstrates that RP-6306 promotes rapid mitotic entry, DNA damage, and mitotic catastrophe, triggering PANoptosis. To improve targeting, membrane-derived vesicles deliver RP-6306 with gemcitabine (GEM + RP-6306@BxPC-3M), which suppresses tumor growth in vitro and in vivo and reduces metastasis while enhancing safety.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-delivery-of-the-pkmyt1-inhibitor-rp-6306-mediates-panoptosis-in-pancreatic-cancer-via-mitotic-catastrophe/367693/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-delivery-of-the-pkmyt1-inhibitor-rp-6306-mediates-panoptosis-in-pancreatic-cancer-via-mitotic-catastrophe/367693.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is RP-6306 considered promising for treating pancreatic cancer?","Question",{"text":63,"@type":64},"RP-6306 is a PKMYT1 inhibitor that induces rapid mitotic entry, DNA damage, and mitotic catastrophe, thereby triggering PANoptosis and suppressing PDAC growth.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is PANoptosis in the context of this study?",{"text":68,"@type":64},"PANoptosis is presented as a novel form of programmed cell death associated with mitotic catastrophe, linking multiple cell-death pathways and generating highly immunogenic effects within tumor matrices.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the vesicle formulation improve the therapy compared with gemcitabine alone?",{"text":72,"@type":64},"The membrane-derived vesicles deliver a combination of RP-6306 and gemcitabine (GEM + RP-6306@BxPC-3M) to target tumor cells more specifically, inhibit tumor growth and metastasis, and exhibit improved safety and antitumor efficacy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367693,1790334537,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTargeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe  \nJingyun Chen 1,5, Jianghao Ren1,5, Chaolei Zhang 1,5, Yang Lv2, Jingbin Zhou2, Weiliang Jiang3, Chaojie Huang4 ✉ and Liping Cao 1 ✉  \n© The Author(s) 2025  \n\n|  | Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor often diagnosed in advanced stages due to its subtle early symptoms, making surgical options nonviable and requiring systemic chemotherapy. Current treatments mainly utilize gemcitabine, which provides limited efﬁcacy. PKMYT1, a serine/threonine protein kinase crucial for cell cycle regulation, is overexpressed in PDAC and correlates with poor prognosis. Treatment with the PKMYT1 inhibitor RP-6306 promotes rapid mitotic entry, resulting in DNA damage and mitotic catastrophe, thereby inducing PANoptosis. RP-6306 effectively inhibits PDAC growth in vitro and in vivo, and shows enhanced anti-tumor activity when combined with gemcitabine, also reducing metastasis. However, gemcitabine has notable systemic toxicity. To target cancer cells more speciﬁcally, we utilized vesicles derived from cell membranes (BxPC-3M) to deliver a combination of RP-6306 and gemcitabine (GEM + RP-6306@BxPC-3M) . This formulation effectively targets homotypic tumor cells and signiﬁcantly inhibits tumor growth both in vitro and in vivo. These ﬁndings highlight the role of RP-6306 in inducing PANoptosis, characterize PANoptosis as a novel form of cell death associated with mitotic catastrophe, and conﬁrm the synergistic antitumor activity of RP-6306 and gemcitabine in PDAC. Moreover, GEM + RP-6306@BxPC-3M exhibits improved safety |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| and enhanced antitumor efﬁcacy. |  |  |\n|  | Cell Death and Disease (2025)16:526; [https://doi.org/10.1038/s41419-025-07835-2](https://doi.org/10.1038/s41419-025-07835-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nPancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer and is highly malignant. In recent years, immunotherapy and targeted therapy have made some progress in the treatment of pancreatic cancer [1, 2] . Dysregulation of protein kinases plays a crucial role in the pathogenesis of many autoimmune and oncogenic diseases, making protein kinase antagonists vital therapeutic targets [3] . However, the majority of FDA-approved kinase inhibitors target members of the EGFR, VEGFR, and JAK families, with fewer options available for serine/ threonine protein kinases [3, 4] . Since the serine/threonine protein kinase family is closely linked to the pathogenesis of pancreatic cancer, inhibitors targeting these kinases hold promise as effective treatments for this disease [4] .  \nThe G2 checkpoint in the cell cycle is critical for cancer cells exposed to DNA-damaging agents, providing time for DNA repair before mitosis [5] . Targeting this checkpoint is a viable therapeutic strategy to inhibit cancer growth. WEE1 and PKMYT1 (MYT1) are two protein kinases that regulate the activity of CDK complexes through inhibitory phosphorylation [6] . PKMYT1 is overexpressed in many tumors characterized by replication stress markers, and PKMYT1 inhibitors have shown efﬁcacy in preclinical, in vitro, and in vivo models [6, 7] . RP-6306, a PKMYT1 inhibitor, effectively  \ntargets CCNE1-ampliﬁed tumor cells and shows enhanced efﬁcacy when combined with agents like hydroxyurea or gemcitabine [8] . A recent Phase I study showed that the PKMYT1 inhibitor lunresertib, combined with FOLFIRI, was effective in a heavily pretreated population of patients with advanced gastrointestinal cancers harboring CCNE1 ampliﬁcation and FBXW7 mutations.  \nCell death, a pivotal strategy in cancer therapy, integrates apoptosis, necroptosis, and pyroptosis—each traditionally viewed as distinct modalities of programm","cbCaibyD2yOSgRM3","https://ap.wps.com/l/cbCaibyD2yOSgRM3","pdf",23338532,18,"English","# Introduction\n## Cell cycle checkpoint and PKMYT1 targeting\n## PANoptosis as programmed cell death paradigm\n## Vesicle-based delivery systems","[{\"question\":\"Why is RP-6306 considered promising for treating pancreatic cancer?\",\"answer\":\"RP-6306 is a PKMYT1 inhibitor that induces rapid mitotic entry, DNA damage, and mitotic catastrophe, thereby triggering PANoptosis and suppressing PDAC growth.\"},{\"question\":\"What is PANoptosis in the context of this study?\",\"answer\":\"PANoptosis is presented as a novel form of programmed cell death associated with mitotic catastrophe, linking multiple cell-death pathways and generating highly immunogenic effects within tumor matrices.\"},{\"question\":\"How does the vesicle formulation improve the therapy compared with gemcitabine alone?\",\"answer\":\"The membrane-derived vesicles deliver a combination of RP-6306 and gemcitabine (GEM + RP-6306@BxPC-3M) to target tumor cells more specifically, inhibit tumor growth and metastasis, and exhibit improved safety and antitumor efficacy.\"}]","Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe | PDF",1790172065,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6b5a7e0630704295e0e49579838bcba.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73ea7b251f8b058593c0956387c49759.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ad7fe7b196a465ff7456841d25085ad.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61ace654b43ad5aca513570f9debb9bf.webp",980,1301]